SEC Form 4 · accession 0001179110-19-001051
ABIOMED INC · ABMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Weber
Officer — Chief Operating Officer
Period of report
Jan 25, 2019
Accepted (ET)
Jan 29, 2019 · 5:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000815094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 par valueF5 | Jan 25, 2019 | M | 14,000 | $22.44 | A | 161,842 | D | |
| Common Stock, $.01 par valueF5 | Jan 25, 2019 | M | 10,000 | $23.15 | A | 171,842 | D | |
| Common Stock, $.01 par valueF6,F7 | Jan 25, 2019 | S | 10,195 | $350.3718 | D | 161,647 | D | |
| Common Stock, $.01 par valueF6,F8 | Jan 25, 2019 | S | 5,965 | $351.4603 | D | 155,682 | D | |
| Common Stock, $.01 par valueF6,F9 | Jan 25, 2019 | S | 4,850 | $352.6305 | D | 150,832 | D | |
| Common Stock, $.01 par valueF6,F10 | Jan 25, 2019 | S | 2,990 | $353.3219 | D | 147,842 | D | |
| Common Stock, $.01 par value | holding | — | — | — | 15,497 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F5,F1 | $22.44 | Jan 25, 2019 | M | 14,000 | D | May 22, 2013 | May 22, 2022 | Common Stock | 14,000 | 0 | D |
| Stock Option (Right to Buy)F2,F5,F1 | $23.15 | Jan 25, 2019 | M | 10,000 | D | May 14, 2014 | May 14, 2023 | Common Stock | 10,000 | 13,000 | D |
| Stock Option (Right to Buy)F2,F3 | $21.55 | holding | — | — | — | May 14, 2015 | May 14, 2024 | Common Stock | 0 | 15,000 | D |
| Stock Option (right to buy)F2,F3 | $66.25 | holding | — | — | — | May 13, 2016 | May 13, 2025 | Common Stock | 0 | 10,000 | D |
| Stock Option (right to buy)F4,F3 | $99.62 | holding | — | — | — | May 24, 2017 | May 24, 2026 | Common Stock | 0 | 7,000 | D |
| Stock Option (right to buy)F4,F3 | $134.51 | holding | — | — | — | May 15, 2018 | May 15, 2027 | Common Stock | 0 | 8,000 | D |
| Stock Option (right to buy)F4,F3 | $381.97 | holding | — | — | — | May 16, 2019 | May 16, 2028 | Common Stock | 0 | 6,500 | D |
Explanation of responses
- F1This option becomes exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- F10This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $353.0000 and $353.5700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F2Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- F3These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- F4Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- F5Exercise of stock options pursuant to reporting owners 10b5-1 plan.
- F6Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- F7This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $350.0000 and $350.9700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F8This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $351.0200 and $351.9600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F9This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $352.0200 and $352.9550. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.